Carrick Therapeutics Ltd. logo

Carrick Therapeutics Ltd.

Carrick Therapeutics is building an innovative portfolio of first-in-class oncology therapies that target the most aggressive and resistance forms of cancer, with research and development teams located in Dublin, Ireland, and Oxford, UK.

Carrick Therapeutics Chief Executive Dr. Elaine Sullivan, is a former Vice President for research and development functions at US pharmaceutical giant Eli Lilly and UK medical leader AstraZeneca.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.carricktherapeutics.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Belfield Innovation Park University College Belfield
Dublin 4
Ireland
Email
Contact Number

Carrick Therapeutics is building an innovative portfolio of first-in-class oncology therapies that target the most aggressive and resistance forms of cancer, with research and development teams located in Dublin, Ireland, and Oxford, UK.

Carrick Therapeutics Chief Executive Dr. Elaine Sullivan, is a former Vice President for research and development functions at US pharmaceutical giant Eli Lilly and UK medical leader AstraZeneca.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/carrick-therapeutics” connections=”true” suffix=””]

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance and tailored to an individual patients tumour.

Carrick Therapeutics has partnered with a network of clinicians and scientists, including Cancer Research UK, and researchers at Cambridge, Imperial College London, and Oxford.

In Oct 2016, Carrick Therapeutics raised $95Mn in a series A funding round led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, GV (Google Ventures), and Lightstone Ventures.